Home/Pipeline/Wee1 Inhibitor

Wee1 Inhibitor

Oncology

PreclinicalActive

Key Facts

Indication

Oncology

Phase

Preclinical

Status

Active

Company

Schrodinger

About Schrodinger

Schrödinger is a computational science pioneer with a dual-business model combining high-margin software licensing with internal drug discovery. Founded in 1990, the company has built a sophisticated, physics-based platform that is widely adopted by pharmaceutical and materials science organizations. Its strategy validates its technology through internal deployment in a therapeutic pipeline, aiming to create diversified revenue streams and capture value across the discovery value chain.

View full company profile

Therapeutic Areas

Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active